¼¼°èÀÇ ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀå
Needle Free Diabetes Care
»óǰÄÚµå : 1794514
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 284 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀº 2030³â±îÁö 168¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 131¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 168¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Àν¶¸° ÁÖÀÔ±â´Â CAGR 3.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 56¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àν¶¸° ÆÐÄ¡ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 5.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 36¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹«¹Ù´Ã ´ç´¢º´ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 36¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 34¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 7.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.8%¿Í 3.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹Ù´Ã ¾øÀ½ ´ç´¢º´ ÄÉ¾î ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹«¹Ù´Ã ´ç´¢º´ Ä¡·á°¡ ¸¸¼ºÁúȯ °ü¸®¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¹«¹Ù´Ã ´ç´¢º´ °ü¸® ±â¼úÀº ±âÁ¸ÀÇ ¹Ù´ÃÀ» ÀÌ¿ëÇÑ Æ÷µµ´ç ¸ð´ÏÅ͸µ°ú Àν¶¸° Åõ¿©¿¡ µû¸¥ ºÒÆíÇÔ, ºÒÆíÇÔ, À§Çè¿¡ ´ëóÇϱâ À§ÇØ °³¹ß ¹× äÅõǰí ÀÖ½À´Ï´Ù. ¸¹Àº ȯÀڵ鿡°Ô ¹Ýº¹ÀûÀ¸·Î ¼Õ°¡¶ôÀ» Â°Å³ª Àν¶¸°À» ÁÖ»çÇÏ´Â °ÍÀº ÅëÁõ, ÇǺΠ¿°Áõ, ºÒ¾ÈÀ» À¯¹ßÇϰí Ä¡·á ¼øÀÀµµ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¹«¹Ù´Ã ½Ã½ºÅÛÀº ÅëÁõÀÌ ¾ø°í, »ç¿ëÇϱ⠽±°í, ºñħ½ÀÀû ¶Ç´Â ÃÖ¼Ò Ä§½ÀÀû ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ±â¼ú¿¡´Â °æÇÇ ÆÐÄ¡, Á¦Æ® ÀÎÁ§ÅÍ, ·¹ÀÌÀú ±â¹Ý ÀåÄ¡, ¸¶ÀÌÅ©·Î´Ïµé ¾î·¹ÀÌ, °£Áú¾×, ¶¡, ºû ½ÅÈ£¸¦ ÀÌ¿ëÇÏ´Â ºñħ½ÀÀû Æ÷µµ´ç ¸ð´ÏÅÍ µîÀÌ ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí Áö¼ÓÇ÷´çÃøÁ¤±â(CGM)¿Í ½º¸¶Æ® ¼¾¼­°¡ ¼öµ¿ ¸ð´ÏÅ͸µ ¹æ½ÄÀ» ´ëüÇϰí ÀÖ½À´Ï´Ù. Àν¶¸° Åõ¿©¿Í ¸ð´ÏÅ͸µ ±â´ÉÀ» ÅëÇÕÇÑ ÀåÄ¡µµ µîÀåÇÏ¿© º¸´Ù Á¤È®ÇÏ°í °³ÀÎÈ­µÈ Ç÷´ç Á¶ÀýÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. »îÀÇ Áú(QOL)°ú Àå±âÀûÀÎ Áúº´ ÀÚ°¡ °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Åø¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

»õ·Î¿î ±â¼úÀº ¾î¶»°Ô Á¢±Ù¼º°ú È¿À²¼ºÀ» ³ôÀ̰í Àִ°¡?

¹ÙÀÌ¿À¼¾¼­ ±â¼ú, ¼ÒÇüÈ­, ¹«¼±Åë½ÅÀÇ ¹ß´Þ·Î º¸´Ù Á¤È®ÇÏ°í ¹ÝÀÀ¼ºÀÌ ³ôÀº ¹«Ä§ ¼Ö·ç¼ÇÀÇ °³¹ßÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÇǺΠ¼¾¼­¸¦ »ç¿ëÇÏ´Â CGMÀº ÇöÀç ½º¸¶Æ®ÆùÀ̳ª Àν¶¸° ÆßÇÁ¿¡ ½Ç½Ã°£À¸·Î µ¥ÀÌÅ͸¦ Àü¼ÛÇÏ¿© ¹°¸®Àû Áß´Ü ¾øÀÌ Áö¼ÓÀûÀÎ ÃßÀûÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÁÖ»ç¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê°í °í¾ÐÀÇ À¯·Î¸¦ ÅëÇØ Àν¶¸°À» Åõ¿©ÇÏ´Â Á¦Æ® ÀÎÁ§ÅÍ´Â Åõ¿© Á¤È®µµ Çâ»ó°ú Á¶Á÷ ¿Ü»ó °¨¼Ò¸¦ À§ÇØ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

±¤ÇÐ ½ÅÈ£, ÀüÀڱ⠽ÅÈ£, ÃÊÀ½ÆÄ ½ÅÈ£¸¦ ÀÌ¿ëÇÑ ºñħ½ÀÀû Ç÷´ç ¸ð´ÏÅ͸µ ÀåÄ¡°¡ Ȱ¹ßÈ÷ ¿¬±¸µÇ°í ÀÖÁö¸¸, ½Å·ÚÇÒ ¼ö ÀÖ´Â Á¤È®µµ¸¦ ´Þ¼ºÇÏ´Â °ÍÀº ¿©ÀüÈ÷ °úÁ¦ÀÔ´Ï´Ù. µðÁöÅÐ Çコ Ç÷§ÆûÀº ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ¿ø°Ý ¸ð´ÏÅ͸µ°ú ´õ ³ÐÀº ¸¸¼ºÁúȯ °ü¸® »ýŰ迡 ÅëÇÕµÉ ¼ö ÀÖµµ·Ï ÀÌµé ±â±â¿Í ¿¬µ¿µÇ°í ÀÖ½À´Ï´Ù. ¹èÅ͸® È¿À²¼º, »ç¿ëÀÚ ÀÎÅÍÆäÀ̽º µðÀÚÀÎ, µ¥ÀÌÅÍ ½Ã°¢È­ ÅøÀº ÀÏ»óÀûÀÎ »ç¿ë ÆíÀǼº°ú ±¤¹üÀ§ÇÑ º¸±ÞÀ» Áö¿øÇϱâ À§ÇØ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

¾î¶² ÃÖÁ¾»ç¿ëÀÚ¿Í ÄÉ¾î ¸ðµ¨ÀÌ ¹Ù´Ã ¾ø´Â ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí Àִ°¡?

¹Ù´Ã ¾ø´Â ´ç´¢º´ ÀåÄ¡ÀÇ ÁÖ¿ä »ç¿ëÀÚ´Â Æí¾ÈÇÔ, ÆíÀǼº, Ä¡·á ¼øÀÀµµ¸¦ ³ôÀ̰íÀÚ ÇÏ´Â Á¦1Çü ¹× 2Çü ´ç´¢º´ ȯÀÚµéÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¼Ò¾Æ ȯÀÚ, ³ëÀÎ, ¹Ù´Ã °øÆ÷Áõ ȯÀڴ ƯÈ÷ ºñħ½ÀÀû ¿É¼ÇÀÇ ÇýÅÃÀ» ¹ÞÀ» °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ÀçÅà ¹× ¿ø°Ý Áø·á ¸ðµ¨Àº ÅëÁ¦·ÂÀ» À¯ÁöÇϸ鼭 º´¿ø ¹æ¹®À» ÃÖ¼ÒÈ­ÇÏ´Â ÀÚ°¡ Á¶ÀÛ ¹× ¿þ¾î·¯ºí ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÀÇ·áÁø°ú ´ç´¢º´ ±³À°Àڵ鵵 ȯÀÚ °ü¸® °èȹ¿¡ ¹«¹Ù´Ã ÀåÄ¡¸¦ µµÀÔÇÏ¿© ȯÀÚ¿ÍÀÇ °ü°è¸¦ °³¼±Çϰí ÇÕº´ÁõÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¾à±¹, ¿ø°ÝÀÇ·á Ç÷§Æû, º¸Çè»çµéÀº ¸ÂÃãÇü ÀÇ·á °èȹÀÇ ÀÏȯÀ¸·Î ÀÌ·¯ÇÑ ±â±â¸¦ Áö¿øÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ´ç´¢º´ À¯º´·üÀÌ ³ô°í ÀÓ»ó ÀÎÇÁ¶ó°¡ Á¦ÇÑµÈ Áö¿ª¿¡¼­ ¹«Ä§ ±â¼úÀº ±âÁ¸ ÀÇ·á ½Ã½ºÅÛÀÇ ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ´Â È®Àå °¡´ÉÇÑ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù.

¹Ù´Ã¾ø´Â ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

¹Ù´Ã ¾ø´Â ´ç´¢º´ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ ³ªÀº ȯÀÚ Ä£È­ÀûÀÎ °ü¸® ÅøÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ¼¾¼­ ±â¼ú, ¿þ¾î·¯ºí ÀÏ·ºÆ®·Î´Ð½º, ¹«¼± µ¥ÀÌÅÍ ÅëÇÕÀÇ ¹ßÀüÀº ±â±âÀÇ ¼º´É°ú »ç¿ëÀÚ °æÇèÀ» Çâ»ó½Ãŵ´Ï´Ù. ÀÚ°¡ ¸ð´ÏÅ͸µ°ú Àå±âÀûÀÎ Áúº´ °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ÒºñÀÚÀÇ Ã¤ÅÃÀ» ÃËÁøÇÕ´Ï´Ù. µðÁöÅÐ Çコ »ýŰèÀÇ È®ÀåÀº ¹«Ä§ ÀåÄ¡¿Í ¸ð¹ÙÀÏ ¾Û ¹× Ŭ¶ó¿ìµå Ç÷§ÆûÀÇ ÅëÇÕÀ» ÃËÁøÇÕ´Ï´Ù. ¼Ò¾Æ ¹× ³ëÀÎÀÇ·á ¸ðµ¨¿¡¼­´Â ¾ÈÀü¼º°ú ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â ¹«Åë ¼Ö·ç¼ÇÀÌ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ºñħ½ÀÀû Áø´Ü¿¡ ´ëÇÑ ÅõÀÚ·Î ¿©·¯ Áö¿ª¿¡¼­ Á¦Ç° °³¹ß ¹× ½ÃÀå °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

µð¹ÙÀ̽º À¯Çü(Àν¶¸° ÁÖÀÔ±â, Àν¶¸° ÆÐÄ¡, Àν¶¸° Ææ, Àν¶¸° ÆßÇÁ, Á¦Æ® ÀÎÁ§ÅÍ), ÃÖÁ¾»ç¿ëÀÚ(ȨÄɾî ÃÖÁ¾»ç¿ëÀÚ, Áø´Ü ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, º´¿ø & Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Needle Free Diabetes Care Market to Reach US$16.8 Billion by 2030

The global market for Needle Free Diabetes Care estimated at US$13.1 Billion in the year 2024, is expected to reach US$16.8 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Insulin Infuser, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$5.6 Billion by the end of the analysis period. Growth in the Insulin Patches segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 7.5% CAGR

The Needle Free Diabetes Care market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Needle-Free Diabetes Care Market - Key Trends & Drivers Summarized

Why Is Needle-Free Diabetes Care Attracting Attention in Chronic Disease Management?

Needle-free diabetes care technologies are being developed and adopted to address the discomfort, inconvenience, and risks associated with traditional needle-based methods of glucose monitoring and insulin delivery. For many patients, repeated finger-pricking and insulin injections cause pain, skin irritation, and anxiety, which can impact adherence to treatment. Needle-free systems aim to improve patient compliance by offering painless, user-friendly, and non-invasive or minimally invasive alternatives.

These technologies include transdermal patches, jet injectors, laser-based devices, microneedle arrays, and non-invasive glucose monitors that use interstitial fluid, sweat, or optical signals. Wearable continuous glucose monitors (CGMs) and smart sensors are increasingly replacing manual monitoring. Devices that integrate insulin delivery with monitoring capabilities are also emerging, allowing for more precise and personalized glycemic control. The increasing emphasis on quality of life and long-term disease self-management is fueling interest in these innovative tools.

How Are Emerging Technologies Enhancing Accessibility and Efficiency?

Advancements in biosensor technology, miniaturization, and wireless communication are driving development of more accurate and responsive needle-free solutions. CGMs using skin sensors now transmit real-time data to smartphones or insulin pumps, enabling continuous tracking without physical disruption. Jet injectors, which deliver insulin through high-pressure streams without needles, are being refined to offer better dosing accuracy and reduced tissue trauma.

Non-invasive blood glucose monitoring devices using optical, electromagnetic, or ultrasound signals are under active research, although achieving reliable accuracy remains a challenge. Digital health platforms are increasingly linked with these devices, allowing remote monitoring by healthcare providers and integration into broader chronic care ecosystems. Battery efficiency, user interface design, and data visualization tools are being improved to support daily usability and broader adoption.

Which End-Users and Care Models Are Driving Demand for Needle-Free Solutions?

The primary users of needle-free diabetes devices include type 1 and type 2 diabetes patients seeking comfort, convenience, and better treatment adherence. Pediatric patients, elderly individuals, and needle-phobic users are particularly likely to benefit from non-invasive options. Home-based and remote care models are helping expand demand for self-operated and wearable solutions that minimize clinic visits while maintaining control.

Healthcare providers and diabetes educators are also incorporating needle-free devices into patient management plans to improve engagement and reduce complications. Pharmacies, telemedicine platforms, and insurance providers are beginning to support these devices as part of personalized health plans. In regions with high diabetes prevalence and limited clinical infrastructure, needle-free technologies offer scalable alternatives that reduce the burden on traditional healthcare systems.

Growth in the Needle-Free Diabetes Care Market Is Driven by Several Factors…

Growth in the needle-free diabetes care market is driven by several factors. Increasing diabetes prevalence worldwide demands better and more patient-friendly management tools. Advancements in sensor technology, wearable electronics, and wireless data integration improve device performance and user experience. Rising awareness of self-monitoring and long-term disease control supports consumer adoption. Expansion of digital health ecosystems encourages the integration of needle-free devices with mobile apps and cloud platforms. Pediatric and geriatric care models favor painless solutions that improve safety and compliance. Regulatory approvals and investment in non-invasive diagnostics are accelerating product development and market entry across multiple regions.

SCOPE OF STUDY:

The report analyzes the Needle Free Diabetes Care market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Device Type (Insulin Infuser, Insulin Patches, Insulin Pens, Insulin Pumps, Jet Injectors); End-Use (Homecare End-Use, Diagnostic Centers End-Use, Hospitals & Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â